Coherus BioSciences Stock News

AQR Capital Management LLC lessened its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 75.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,007 shares of the biotechnology companys stock after selling 84,533 shares during the period. AQR []

Wall Street analysts expect Coherus BioSciences, Inc. (NASDAQ:CHRS) to post sales of $83.32 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Coherus BioSciences earnings, with estimates ranging from $80.23 million to $86.40 million. Coherus BioSciences posted sales of $110.42 million in the same quarter last year, which would []

Charles Schwab Investment Management Inc. boosted its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 1.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 475,678 shares of the biotechnology companys stock after acquiring an additional 8,735 shares during the []

Related Stocks: EVH , TLMD , CMAX , EA , CHRS , EXC , GDP , TBT , OAS , CANO , MARA ,

The FDA bestows an Orphan Drug designation to Coherus (CHRS) and partner Junshi's toripalimab for the treatment of esophageal cancer.

REDWOOD CITY, Calif. and SHANGHAI, China, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation (ODD) for toripalimab for the treatment of esophageal cancer. Orphan drug designation is granted to drugs and biologics intended to treat rare diseases with a patient population less than 200,000 in the U.S. The designation provides incentives to advance development and commercialization of rare disease drugs.

SHANGHAI, China and REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc. (Coherus, Nasdaq: CHRS) announced today that the United States Food and Drug Administration ("FDA") has granted Orphan Drug Designation (ODD) for toripalimab for the treatment of esophageal cancer. Orphan drug designation is granted to drugs and biologics intended to treat rare diseases with a patient population less than 200,000 in the U.S. The designation provides incentives to advance development and commercialization of rare disease drugs.

Coherus BioSciences, Inc. (CHRS) CEO Dennis Lanfear on Q3 2021 Results - Earnings Call Transcript

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -22.50% and -5.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stoc

Coherus BioSciences (NASDAQ:CHRS) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement.

REDWOOD CITY, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2021 financial results will be released after m

Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Coherus makes a lot of money from its biosim business. Its foray into R&D is slowly getting derisked with positive data.

REDWOOD CITY, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- It is with profound sadness that Coherus BioSciences, Inc. (Nasdaq: CHRS) announces the unexpected passing of board member Alan C. Mendelson. H

REDWOOD CITY, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced the United States Food and Drug Administration (FDA) has accepted for r